

Change of Leadership & Company Secretary

HeraMED Limited (ASX:HMD) ('HeraMED' or the 'Company'), a medical data and technology company leading the digital transformation of maternity care, today announces the following changes to leadership of the Company and change in Company Secretary.

Leadership changes

Dr Ron Weinberger has stepped down from his Executive role and will transition his executive responsibilities in an orderly manner. Dr Weinberger remains a Director in the short term until a suitable candidate is appointed. As announced on 11 March 2024, the Company is currently engaged in discussions with several candidates that will help support the commercialisation of HeraCARE in its next phase.

Ms Anoushka Gungadin, Executive Vice-President ANZ has been appointed CEO of the Company.

Anoushka Gungadin is an experienced CEO, Board Director, and cross-border executive, with a career spanning across four continents. She is currently on the council of the Deakin University. She is the Australian lead for TiE Women, a global mentoring and investment platform for female entrepreneurs. She is a speaker and researcher on inclusive leadership and cultural intelligence.

Her previous experience includes founding CEO of the Australia India Chamber of Commerce set up to drive bilateral economic relationships. She headed up finance and accounts for an International law firm for 10 years in Beijing. She has consulted and worked with brands including Mondelez, l'Oreal, Bank of Indonesia, Reliance, Rhipe-Crayon and more.

A trained economist, she holds an MBA and is a certified professional coach.

Appointment of CFO & Company Secretary

In accordance with ASX Listing Rule 3.16.1, Cameron Jones, Managing Director of Bio101 Financial Advisory Pty Ltd 'Bio101' has been appointed Company Secretary of the Company. The appointment of Cameron Jones as Company Secretary follows the resignation of Jonathan Hart. The Board wishes to thank Mr Hart for his services to the company.

Cameron has also been appointed as CFO of the Company with Bio101 to provide CFO and finance function services to the Company as it transitions its financial operations from Israel to Australia.

Cameron is a finance executive with experience as CFO and Company Secretary of ASX Listed and private healthcare companies and has supported companies through IPOs, capital raising and M&A transactions. Cameron is a Chartered Accountant and holds a Certificate in Governance from the Governance Institute of Australia.

Voluntary Suspension

As outlined in ASX announcement titled *Supplemental information – Voluntary Suspension* on 8 April 2024, the Company requests that the suspension remains in place until the Company releases an announcement in relation to the restructure of the business, the financial position of the Company, associated capital requirements and proposed financing to fund ongoing operations of the business. The discussions referred to above are ongoing, and at this stage it is difficult to predict a timetable for their conclusion however the Company is working to finalise the above matters urgently and currently intends to make that announcement by 29 April 2024. Further updates will be provided in due course.

About Bio101

Bio101 is a financial services firm providing outsourced CFO, accounting, taxation, company secretarial and strategic financial advisory services specialising in the healthcare sector. Our clients include ASX listed companies, small start-ups, spin outs from research institutes, venture capital investee companies, foreign wholly owned subsidiaries (including NASDAQ and TSX listed companies), companies seeking to list on the ASX and not for profits. Bio101 has 3 experienced Directors leading a team of chartered accountants, company secretaries, bookkeepers and a graphic designer.

-ENDS-

This announcement has been authorised by the Board of HeraMED Limited.

CEO

Anoushka Gungadin

T: +61 431 131 649

E: anoushka@hera-med.com

Company Secretary

Cameron Jones

T: +61 400 086 399

E: cameron.jones@bio101.com

Investor Relations

Tim Chapman

T: +61 419 897 062

E: tchapman@claritycap.com.au

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.

ANNEXURE – CEO APPOINTMENT AND REMUNERATION TERMS

Position	Chief Executive Officer
Commencement Date	9 April 2024
Term	Appointment is on an on-going basis, subject to termination by either party (refer to Termination and Notice Period Below)
Fixed Remuneration	US\$204,000 per annum
Termination and Notice Period	4 weeks' notice from either party